Dr. Ywan-Feng Li has 20 years of experience in the evaluation and regulation of biologics and biotechnological products. Dr. Li is in charge of the regulatory affair department since joining Eirgenix in 2022.

In 1999-2001, she worked as a research associate fellow in Depart. OB/GYN at the Veterans General Hospital-Taipei, where she focused on the studies of metastasis-related markers and Ab for radio-immunodetection of tumors. In 2001-2017, she worked as the CMC reviewer and then director of the Pharmaceutical Science Division at the Center for Drug evaluation-Taiwan (CDE). During 15-year stay in the regulatory agency, she established expertise in the evaluation and regulation of biologics/biotechnological products. In 2017, she transferred career to the biotech industry and served as the vice president of Medical & Clinical Center of the UnitedBioPharma Inc. with a role in oversee and management of the clinical development of several mAb products.

Dr. Li graduated from University of North Carolina at Chapel Hill followed by post-doc research at Fred Hutchinson Cancer Research Center, USA, and National Yang-Ming University, Taiwan.